Erika Paige Hamilton

50PUBLICATIONS
464CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsClinical midwiferyHealth and ecological risk assessmentPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (50)

|Aug 24, 2026
Elacestrant in Combination with Everolimus for Estrogen Receptor-Positive, HER2-Negative Previously Treated Advanced Breast Cancer: Results from ELEVATE.

|Jan 08, 2026
DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer.

Komal Jhaveri, Sherene Loi, Erika Hamilton

|Dec 17, 2025
ER degradation for ER+/HER2- advanced or metastatic breast cancer: a phase 1 trial.

Erika Hamilton, Rachel M Layman, David Cosgrove

|Dec 10, 2025
HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Veronique Dieras, Giuseppe Curigliano, Miguel Martin

|Nov 10, 2025
A Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of a Folate Receptor Alpha Vaccine in Patients with Triple-Negative Breast Cancer.

Keith L Knutson, Hala Abu-Fares, Patricia Keating

|Nov 07, 2025
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast Cancer.

Maxwell R Lloyd, Caroline M Weipert, Azka Ali

Pageof 9

Frequent Collaborators

7 joint publications

Miguel Martin

6 joint publications

Komal L Jhaveri

5 joint publications

Peter Schmid

5 joint publications

Kevin Kalinsky